| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Sodium-glucose cotransporter (SGLT). Vexibinol has been identified as an SGLT inhibitory flavonoid. The compound also exhibits antioxidant, antimalarial, antibacterial, and anti-inflammatory activities. Vexibinol (250 mg/kg) inhibits carrageenan-induced paw edema in rats.
|
|---|---|
| ln Vitro |
In a dose-dependent manner, sophoraflavanone G (0 - 100 μM; 24 hours) decreases the viability of HL-60 cells [1]. Sophoraflavanone G (0 -100 μM; 24 hours) downregulates Bcl-2 and Bcl-xL, activates caspase-3 and caspase-9, and causes apoptosis in HL-60 cells. Sophoraflavanone G (0–40 μM; 24 hours) inhibits MDA-MB-231 cell viability in a concentration-dependent manner; the IC50 value is 29.7 ± 5.2 μM[2]. It also upregulates Bax and releases cytochrome c from mitochondria into the cytoplasm, enabling apoptosis through the mitochondria-mediated “intrinsic” pathway [1].
Vexibinol exhibits antioxidant, antimalarial, antibacterial, and phytometabolic activities. It has been identified as an SGLT inhibitory flavonoid. Vexibinol (250 mg/kg) inhibits carrageenan-induced paw edema in rats, demonstrating anti-inflammatory activity. The compound is a tetrahydroxyflavonoid belonging to the 4'-hydroxyflavonoid class. |
| ln Vivo |
In vivo, vexibinol (250 mg/kg) inhibits carrageenan-induced paw edema in rats, demonstrating significant anti-inflammatory activity. The compound has also been studied for its antioxidant, antimalarial, and antibacterial activities. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme assays for vexibinol involve measuring its inhibitory effects on SGLT or other enzymatic targets. SGLT activity is measured using radiolabeled glucose uptake assays in the presence of various concentrations of vexibinol. The compound has been identified as an SGLT inhibitory flavonoid.
|
| Cell Assay |
In vitro cellular assays for vexibinol involve treating cells with the compound and measuring antioxidant activity, glucose uptake, or inflammatory responses. Cells are treated with various concentrations of vexibinol, and reactive oxygen species levels, glucose uptake, or cytokine production are measured. Vexibinol exhibits antioxidant and anti-inflammatory activities.
|
| Animal Protocol |
In vivo animal studies for vexibinol typically involve administration to rodent models of inflammation. Vexibinol (250 mg/kg) inhibits carrageenan-induced paw edema in rats. Efficacy is assessed by measuring paw swelling and inflammatory markers. The compound's anti-inflammatory activity is demonstrated in this model.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for vexibinol is limited. The compound has a molecular weight of 424.49 and a molecular formula of C25H28O6. It is a tetrahydroxyflavonoid. Further pharmacokinetic studies are needed to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of vexibinol are limited. The compound exhibits antioxidant, antimalarial, antibacterial, and anti-inflammatory activities, suggesting a favorable safety profile. Vexibinol (250 mg/kg) inhibits carrageenan-induced paw edema in rats without overt toxicity. Comprehensive toxicological evaluation is needed before clinical development.
|
| References | |
| Additional Infomation |
Sophoraflavanone G is a tetrahydroxyflavonoid with a structure similar to naringin, but with an additional hydroxyl substituent at the 2' position and a (2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl (lavenderyl) substituent at the 8' position. It possesses antioxidant, antimalarial, antibacterial, and phytometabolic activities. It is a tetrahydroxyflavonoid, belonging to the 4'-hydroxyflavonoid class of compounds, and is also a (2S)-flavan-4-one. Its function is related to (S)-naringin. Sophoraflavanone G has been found in Sophora stenophylla, Sophora moorcroftiana, and other organisms with relevant data.
Vexibinol (Sophoraflavanone G, Kushenol F) is a tetrahydroxyflavonoid with antioxidant, antimalarial, antibacterial, and anti-inflammatory activities. It has a molecular formula of C25H28O6 and a molecular weight of 424.49. Vexibinol (250 mg/kg) inhibits carrageenan-induced paw edema in rats, demonstrating significant anti-inflammatory activity. It has been identified as an SGLT inhibitory flavonoid from Sophora flavescens. |
| Molecular Formula |
C25H28O6
|
|---|---|
| Molecular Weight |
424.493
|
| Exact Mass |
424.188
|
| CAS # |
97938-30-2
|
| PubChem CID |
72936
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
659.3±55.0 °C at 760 mmHg
|
| Melting Point |
173-175℃
|
| Flash Point |
224.8±25.0 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.623
|
| LogP |
6.52
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
684
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(=CC[C@H](CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)O)C(=C)C)C
|
| InChi Key |
XRYVAQQLDYTHCL-CMJOXMDJSA-N
|
| InChi Code |
InChI=1S/C25H28O6/c1-13(2)5-6-15(14(3)4)9-18-20(28)11-21(29)24-22(30)12-23(31-25(18)24)17-8-7-16(26)10-19(17)27/h5,7-8,10-11,15,23,26-29H,3,6,9,12H2,1-2,4H3/t15-,23+/m1/s1
|
| Chemical Name |
(2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
|
| Synonyms |
Kushenol F; (-)-Vexibinol; Vexibinol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~588.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3558 mL | 11.7788 mL | 23.5577 mL | |
| 5 mM | 0.4712 mL | 2.3558 mL | 4.7115 mL | |
| 10 mM | 0.2356 mL | 1.1779 mL | 2.3558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
